Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Operating Expenses (2016 - 2025)

Capricor Therapeutics has reported Operating Expenses over the past 15 years, most recently at $29.2 million for Q4 2025.

  • Quarterly results put Operating Expenses at $29.2 million for Q4 2025, up 54.86% from a year ago — trailing twelve months through Dec 2025 was $108.1 million (up 66.8% YoY), and the annual figure for FY2025 was $108.1 million, up 66.8%.
  • Operating Expenses for Q4 2025 was $29.2 million at Capricor Therapeutics, up from $26.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for CAPR hit a ceiling of $29.2 million in Q4 2025 and a floor of $4.3 million in Q3 2021.
  • Median Operating Expenses over the past 5 years was $12.4 million (2023), compared with a mean of $13.8 million.
  • Peak annual rise in Operating Expenses hit 126.84% in 2021, while the deepest fall reached 9.76% in 2021.
  • Capricor Therapeutics' Operating Expenses stood at $6.4 million in 2021, then surged by 41.49% to $9.0 million in 2022, then soared by 48.12% to $13.4 million in 2023, then soared by 40.82% to $18.8 million in 2024, then soared by 54.86% to $29.2 million in 2025.
  • The last three reported values for Operating Expenses were $29.2 million (Q4 2025), $26.3 million (Q3 2025), and $27.7 million (Q2 2025) per Business Quant data.